Completed PHASE4 INTERVENTIONAL 1-arm NCT01807455

An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine

Sponsor: Galderma R&D

Updated 8 times since 2017 Last updated: Aug 24, 2022 Started: Apr 30, 2013 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acne Scars and is currently completed. Galderma R&D leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Sep 2022 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jan 2021 — Sep 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Galderma R&D

Data source: Galderma R&D

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boom, Belgium